Acadia Pharmaceuticals
ACAD
214 hedge funds and large institutions have $3.47B invested in Acadia Pharmaceuticals in 2015 Q4 according to their latest regulatory filings, with 38 funds opening new positions, 79 increasing their positions, 67 reducing their positions, and 9 closing their positions.
322% more first-time investments, than exits
New positions opened: 38 | Existing positions closed: 9
18% more repeat investments, than reductions
Existing positions increased: 79 | Existing positions reduced: 67
14% more funds holding
Funds holding: 187 → 214 (+27)
7% more capital invested
Capital invested by funds: $3.25B → $3.47B (+$216M)
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
23% less call options, than puts
Call options by funds: $43.4M | Put options by funds: $56.3M
Top Buyers
| 1 |
Westfield Capital Management
Boston,
Massachusetts
|
+$52.1M |
| 2 |
PC
PointState Capital
New York
|
+$15.9M |
| 3 |
State Street
Boston,
Massachusetts
|
+$13.4M |
| 4 |
FCM
Frontier Capital Management
Boston,
Massachusetts
|
+$12.2M |
| 5 |
GTC
Ghost Tree Capital
New York
|
+$8.81M |
Top Sellers
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$60.2M |
| 2 |
ACA
Avoro Capital Advisors
New York
|
-$19.2M |
| 3 |
Jennison Associates
New York
|
-$17.8M |
| 4 |
FAM
Fred Alger Management
New York
|
-$17.3M |
| 5 |
Capital World Investors
Los Angeles,
California
|
-$13.3M |
ACAD Hedge Fund Activity: Q4 2015 in Review
214 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Acadia Pharmaceuticals (ACAD) for Q4 2015, worth a combined $3.47B — up 6.6% from $3.25B a quarter earlier.
Buyers outnumbered sellers: 38 funds opened new ACAD positions and 9 closed out — a net gain of 29 holders — while 79 added to existing stakes and 67 trimmed.
The largest buyer was Westfield Capital Management, opening a new position worth an estimated $52.1M. The largest seller was Point72 Asset Management, cutting an estimated $60.2M.
- 214 institutional investors held Acadia Pharmaceuticals (ACAD) as of Q4 2015, up from 187 in Q3 2015.
- Funds reported $3.47B of Acadia Pharmaceuticals stock for Q4 2015, up 6.6% quarter-over-quarter.
- 38 funds opened new Acadia Pharmaceuticals positions in Q4 2015 and 9 closed out, a net change of +29 holders.
- The largest Acadia Pharmaceuticals buyer in Q4 2015 was Westfield Capital Management, an estimated $52.1M added.
- The largest Acadia Pharmaceuticals seller in Q4 2015 was Point72 Asset Management, an estimated $60.2M sold.
Based on aggregated 13F filings for Q4 2015.